The independent source for health policy research, polling, and news.
2,641-2,660 of 4,003 results
A Kaiser Permanente pain management program in Southern California aims to help patients taper off addictive painkillers. Some doctors and patients see it as a godsend; others complain that patients have been cut off medications they need.
Blue Shield of California is hoping to steer consumers to "preferred" pharmacies where drugs are cheaper and copays lower.
An electronic consulting and referral system adopted by the county’s safety net public health system in 2012 has reduced waiting times for appointments with specialists and eliminated the need for such appointments in a significant number of cases, according to a new study in the journal Health Affairs.
Amid an uproar over high drug prices, three GOP senators are asking the Government Accountability Office to investigate whether the Orphan Drug Act is being abused.
Rand Corp. finds that telehealth encourages patients to seek care for minor illnesses they wouldn’t bother to make an office visit for, raising overall health costs.
Although Republicans flirted with the idea of changing the tax code so that the value of employer-sponsored health insurance is added to workers’ tax liability, House leaders decided to instead keep the ACA’s tax on insurers and employers that provide generous coverage.
After the medical board reinstated the license of doctor who molested patients, one member –now president -- secured a $40 million donation for a pet project from the doctor’s relative. He says the two events are unrelated. Critics are demanding an investigation.
Hundreds of drug brands are being made in giant contract facilities. When a plant shuts down, a widespread drain on supply can result.
A new study shows that 83 percent of the largest patient advocacy groups take contributions from drug, medical device or biotech firms.
“Portability” will likely be a buzz word in the health law repeal-and-replace debate, but the concept raises a number of complicated policy issues.
An aging writer discovers there are worse things than going bald after examining the side effects of a popular hair loss drug purportedly used by President Donald Trump.
Hospice groups are teaming up with specially trained paramedics to deal with common problems that worried patients or families incorrectly think need hospital care.
In direct primary care, a monthly fee covers routine care, limiting insurers' role. But does it really provide better value?
Vermont embarks on a six-year experiment to redesign health care and how it’s paid for.
San Mateo Medical Center is among hundreds of safety-net hospitals in California and across the country that stand to lose big if the federal government slashes support for Medicaid and insurance exchanges.
Rep. Chris Collins’ enthusiastic investments in Australian biotech company Innate Immunotherapeutics preceded share purchases by the Buffalo Republican’s family members, associates and political donors — raising questions from Washington, D.C., to Sydney.
A drug from Marathon Pharmaceuticals has ignited a firestorm on Capitol Hill and beyond. What makes it different than the $750,000 drug that came before it?
One in four doctors practicing in the U.S. is an international medical doctor. Many foreign-born doctors practice in parts of the country where there are doctor shortages.
A federal judge in Texas last month issued a preliminary injunction barring the government from enforcing a rule allowing insurers to refuse to insure dialysis patients who get premium assistance from charity groups.
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
© 2026 KFF